|
Sample
|
Age
|
Treatment effect
|
Vital status
|
PFI (Months)
|
Clusters
|
|---|
|
1
|
66
|
PD
|
1
|
4
|
2
|
|
2
|
54
|
CR
|
1
|
4
|
2
|
|
3
|
59
|
PD
|
1
|
6
|
1
|
|
4
|
66
|
CR
|
1
|
0
|
2
|
|
5
|
75
|
SD
|
1
|
7
|
2
|
|
6
|
56
|
PR
|
1
|
5
|
2
|
|
7
|
70
|
CR
|
1
|
0
|
1
|
|
8
|
62
|
PR
|
0
|
0
|
2
|
|
9
|
72
|
PR
|
1
|
42
|
1
|
|
10
|
44
|
PR
|
0
|
22
|
1
|
|
11
|
70
|
PR
|
1
|
21
|
2
|
|
12
|
71
|
CR
|
0
|
34
|
1
|
|
13
|
66
|
PR
|
0
|
29
|
1
|
|
14
|
52
|
PR
|
0
|
17
|
1
|
|
15
|
66
|
CR
|
0
|
37
|
1
|
|
16
|
54
|
CR
|
0
|
24
|
2
|
- Sixteen patients diagnosed with ovarian high-grade serous carcinoma (HGSC), stage IIIC (FIGO classification 2014), who had started treatment were analysed
- CR complete response, PR partial response, SD stable disease, PD progressive disease
- Vital status: alive = 0, dead = 1. PFI Platinum-free interval. Cluster: Cluster classified by cluster analysis
